GlassScriptPhysician profile
Marina Vaysburd
NPI 1689784712
$68,168.50
in general payments reported to CMS, 2019-2025
48 companies · $65.05 in 2025
The $65.05 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $13K · 2021: $5,955 · 2022: $2,275 · 2023: $3,336 · 2024: $2,062 · 2025: $65.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,293 · Food and Beverage: $1,012 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,292.50 |
| Food and Beverage | $1,011.81 |
| Education | $158.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $31,400.24 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $24,339.18 | 2019-2025 | Tagrisso, Enhertu |
| Janssen Scientific Affairs, LLC | $2,708.08 | 2019-2020 | |
| Pfizer INC. | $966.28 | 2019-2023 | |
| Daiichi Sankyo INC. | $918.79 | 2019-2024 | Enhertu, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $814.11 | 2019-2023 | Opdivo |
| Janssen Biotech, INC. | $734.94 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $589.72 | 2019-2023 | Keytruda |
| Incyte Corporation | $517.03 | 2020-2024 | Jakafi, Pemazyre, Monjuvi |
| Janssen Pharmaceuticals, INC | $494.07 | 2020-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $489.83 | 2019-2022 | |
| Amgen INC. | $482.02 | 2019-2023 | Lumakras |
| Genentech USA, INC. | $295.68 | 2019-2024 | Tecentriq, Venclexta |
| Genzyme Corporation | $289.26 | 2019-2025 | |
| Taiho Oncology, INC. | $232.48 | 2019-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marina Vaysburd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.